0001005201-19-000078.txt : 20190509
0001005201-19-000078.hdr.sgml : 20190509
20190509113107
ACCESSION NUMBER: 0001005201-19-000078
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190507
FILED AS OF DATE: 20190509
DATE AS OF CHANGE: 20190509
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tyree James L
CENTRAL INDEX KEY: 0001324991
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-13111
FILM NUMBER: 19809466
MAIL ADDRESS:
STREET 1: 100 ABBOTT PARK ROAD
CITY: ABBOTT PARK
STATE: IL
ZIP: 60064-6400
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Assertio Therapeutics, Inc
CENTRAL INDEX KEY: 0001005201
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943229046
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 SOUTH SAUNDERS RD
STREET 2: SUITE 300
CITY: LAKE FOREST
STATE: IL
ZIP: 60045
BUSINESS PHONE: (224) 419-7106
MAIL ADDRESS:
STREET 1: 100 SOUTH SAUNDERS RD
STREET 2: SUITE 300
CITY: LAKE FOREST
STATE: IL
ZIP: 60045
FORMER COMPANY:
FORMER CONFORMED NAME: DEPOMED INC
DATE OF NAME CHANGE: 19970408
4
1
wf-form4_155741585078890.xml
FORM 4
X0306
4
2019-05-07
0
0001005201
Assertio Therapeutics, Inc
ASRT
0001324991
Tyree James L
ASSERTIO THERAPEUTICS, INC.
100 SOUTH SAUNDERS ROAD, SUITE 300
LAKE FOREST
IL
60045
1
0
0
0
Common Stock
2019-05-07
4
A
0
39584
0
A
49340
D
Common Stock
2019-05-08
4
M
0
31250
0
A
80590
D
Restricted Stock Units
0.0
2019-05-08
4
M
0
31250
0
D
2019-05-08
2019-05-08
Common Stock
31250.0
0
D
Restricted stock units that vest in full on the first anniversary of the grant date.
Since the date of the reporting person's last ownership report, he transferred 9,756 shares of the Registrant's common stock pursuant to a domestic relations order. The reporting person no longer reports these securities as beneficially owned by him.
Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock.
The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
/s/ Erin R. McQuade, attorney in fact
2019-05-09